Slide 1: Full year results presentation
GROUP LIMITED Full year results presentation August 2019 Allan McCallum – Chairman Peter Crock – Chief Executive Officer 1 Shining light on medicinal cannabis
Slide 2: Disclaimer
Disclaimer This investor presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 Future performance 949 739) (Cann) and comprises written material regarding Cann. This Presentation contains certain ‘forward looking statements’, including but not limited to projections, guidan
Slide 3: Disclaimer
Disclaimer Affiliates All rights reserved None of Cann’s respective advisers or any of their respective affiliates, related bodies corporate, directors, Several photographs contained in this Presentation are the property of Cann and are protected officers, partners, employees and agents, have author
Slide 4: Allan McCallum, Chairman
Allan McCallum Chairman 4 Shining light on medicinal cannabis
Slide 5: Financial results
Financial results 5 Shining light on medicinal cannabis
Slide 6: Cultivation
Cultivation • Most experienced cultivator in Australia – continuous since 2017 with more than 40 harvests • Proven capability to produce medicinal grade cannabis, giving Cann a key intellectual property position • Accelerated breeding program focused on delivering independent genetics • State-of-the
Slide 7: Processing
Processing • Partnered with IDT Australia (ASX:IDT) for manufacturing support in relation to cannabis- based product formulations • Brings excellent capabilities & experience in the manufacture of cGMP quality pharmaceuticals • Provides Cann an integrated pathway through the full supply chain • Extr
Slide 8: Commercial
Commercial • Contract with Victorian Department of Health & Human Services (DHHS) for supply of medicinal cannabis resin • Five-year offtake agreement signed with Aurora Cannabis • Product development & validation on track for commercial sales of Cann products before end of calendar 2019 • Partnersh
Slide 9: Peter Crock, CEO
Peter Crock CEO 9 Shining light on medicinal cannabis
Slide 10: Continued successful production
Continued successful production • Ongoing harvest cycle across the Southern & Northern facilities, which operate at full capacity • More than 40 harvests from a base now including 24 imported varieties • First harvests of internationally sourced genetics completed • Supply of medicinal cannabis from
Slide 11: Key facilities & updated expansion program
Key facilities & updated expansion program • Mildura site purchased for construction of facility comprising world scale greenhouse & associated support areas • Production capacity increased to 70,000kg of dry flower per annum – ability to generate $220-280m in annual revenues • Siteworks completed &
Slide 12: Regulatory approvals
Regulatory approvals • Post year end – manufacturing licences received for Cann’s Southern & Northern facilities • Gives Cann Group all cultivation, production & manufacturing licences in addition to import & export licences • May 2019 – IDT Australia granted manufacturing licence • June 2019 – Auro
Slide 13: Commercial advancements
Commercial advancements • Victorian DHHS takes delivery of first material from Cann Group under the supply contract announced in October 2018 • Offtake agreement with Aurora Cannabis – Cann to supply GMP processed dry flower, extracted resin & manufactured medicinal cannabis products until 2024, rel
Slide 14: Strategic partnerships & research
Strategic partnerships & research • NZ$6 million investment for 20% strategic ownership stake in well positioned NZ medicinal cannabis company Pure Cann New Zealand Limited – technical services agreement signed • MOU with Agriculture Victoria for additional medicinal cannabis research across cultiva
Slide 15: Outlook
Outlook • Progress construction & development of the • IDT manufacturing commencement Mildura facility • Clinical study involvement • Debt funding to be confirmed with finalisation of design revisions • Focus on Australian patient supply • Testing of export pathways with Aurora & commencement of exp
Slide 16: Questions
Questions 16 Shining light on medicinal cannabis
Slide 17: Contacts
GROUP LIMITED CONTACTS: Clive Fanning Head of Investor Relations Cann Group Limited +61 (0)498 000 762 contact@canngrouplimited.com Matthew Wright Investor / Media Relations NWR Communications +61 (0)451 896 420 matt@nwrcommunications.com.au 17 Shining light on medicinal cannabis